These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 17346094

  • 21. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs.
    Farkouh ME, Greenberg BP.
    Am J Cardiol; 2009 May 01; 103(9):1227-37. PubMed ID: 19406264
    [Abstract] [Full Text] [Related]

  • 22. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
    Florentinus SR, Heerdink ER, de Boer A, van Dijk L, Leufkens HG.
    Pharmacoepidemiol Drug Saf; 2005 Jul 01; 14(7):437-41. PubMed ID: 15937867
    [Abstract] [Full Text] [Related]

  • 23. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.
    Vardeny O, Solomon SD.
    Cardiol Clin; 2008 Nov 01; 26(4):589-601. PubMed ID: 18929233
    [Abstract] [Full Text] [Related]

  • 24. The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients.
    Solomon DH, Glynn RJ, Bohn R, Levin R, Avorn J.
    J Rheumatol; 2003 Apr 01; 30(4):792-8. PubMed ID: 12672201
    [Abstract] [Full Text] [Related]

  • 25. Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs.
    Mosis G, Stijnen T, Castellsague J, Dieleman JP, van der Lei J, Stricker BH, Sturkenboom MC.
    Arthritis Rheum; 2006 Aug 15; 55(4):537-42. PubMed ID: 16874797
    [Abstract] [Full Text] [Related]

  • 26. [Cardiovascular toxicity of selective COX-2-inhibitors and classical NSAIDs].
    Lange H, Eberhart L.
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2007 Jul 15; 42(7):514-7. PubMed ID: 17661262
    [Abstract] [Full Text] [Related]

  • 27. [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].
    van den Bemt BJ, Benraad HB, Rasker JJ.
    Ned Tijdschr Geneeskd; 2007 May 12; 151(19):1062-7. PubMed ID: 17552414
    [Abstract] [Full Text] [Related]

  • 28. Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs.
    Jones R, Rubin G, Berenbaum F, Scheiman J.
    Am J Med; 2008 Jun 12; 121(6):464-74. PubMed ID: 18501223
    [Abstract] [Full Text] [Related]

  • 29. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?
    Chen JT, Pucino F, Resman-Targoff BH.
    J Pain Palliat Care Pharmacother; 2006 Jun 12; 20(4):11-32. PubMed ID: 17182503
    [Abstract] [Full Text] [Related]

  • 30. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands.
    Layton D, Souverein PC, Heerdink ER, Shakir SA, Egberts AC.
    Drug Saf; 2008 Jun 12; 31(2):143-58. PubMed ID: 18217790
    [Abstract] [Full Text] [Related]

  • 31. Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks.
    Chan FK.
    Nat Clin Pract Gastroenterol Hepatol; 2006 Oct 12; 3(10):563-73. PubMed ID: 17008926
    [Abstract] [Full Text] [Related]

  • 32. Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal.
    Davies NM, Reynolds JK, Undeberg MR, Gates BJ, Ohgami Y, Vega-Villa KR.
    Expert Rev Neurother; 2006 Nov 12; 6(11):1643-55. PubMed ID: 17144779
    [Abstract] [Full Text] [Related]

  • 33. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.
    Borer JS, Simon LS.
    Arthritis Res Ther; 2005 Nov 12; 7 Suppl 4(Suppl 4):S14-22. PubMed ID: 16168077
    [Abstract] [Full Text] [Related]

  • 34. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S.
    J Clin Pharm Ther; 2017 Feb 12; 42(1):27-38. PubMed ID: 28019014
    [Abstract] [Full Text] [Related]

  • 35. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
    Hermann M, Ruschitzka F.
    Ann Med; 2007 Feb 12; 39(1):18-27. PubMed ID: 17364448
    [Abstract] [Full Text] [Related]

  • 36. The NSAID dilemma: managing osteoarthritis in high-risk patients.
    Roth SH, Anderson S.
    Phys Sportsmed; 2011 Sep 12; 39(3):62-74. PubMed ID: 22030942
    [Abstract] [Full Text] [Related]

  • 37. Clinical implications of nonopioid analgesia for relief of mild-to-moderate pain in patients with or at risk for cardiovascular disease.
    Whelton A.
    Am J Cardiol; 2006 May 08; 97(9A):3-9. PubMed ID: 16675316
    [Abstract] [Full Text] [Related]

  • 38. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM, Reeves MJ, Whelton A.
    Am J Ther; 2007 May 08; 14(1):3-12. PubMed ID: 17303969
    [Abstract] [Full Text] [Related]

  • 39. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.
    Andersohn F, Suissa S, Garbe E.
    Circulation; 2006 Apr 25; 113(16):1950-7. PubMed ID: 16618816
    [Abstract] [Full Text] [Related]

  • 40. Cyclooxygenase-2 inhibitors and cardiovascular risk.
    Solomon SD.
    Curr Opin Cardiol; 2006 Nov 25; 21(6):613-7. PubMed ID: 17053413
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.